Caring Ambassadors Hepatitis C Program Newsletter
www.HepCChallenge.org
August
2008
In The News
Life
Story: Hepatitis C advocate was 49
“Sherri Ziegler was a strong advocate for education about Hepatitis C and
services for those affected by the virus. She helped start the California
Hepatitis Alliance, founded the Nor-Cal Hepatitis C Network, was a founding
member the National Hepatitis C Advocacy Council and a member of the National
Viral Hepatitis Roundtable and the California Hepatitis C Task Force. She often
appeared before legislators in Sacramento and Washington, D.C. All
because she couldn't find any information about the virus when she was
diagnosed.
‘She went in search for information ... searching
out and finding what was out there,’ said her sister, Jeanee Marler of
Paradise. ‘The more she found out, the more depressing (it was) because nothing
was out there.’ Sherri Rae Ziegler, 49, of Yuba City, died June 26 at the
University of California, San Francisco Medical Center due to a brain aneurysm,
according to her family. Born in Sacramento, the longtime Yuba City resident
was a graduate of Yuba City High School. Sherri never knew exactly how she
contracted Hep C, her sister noted.” Read
more…
Natalie Cole says she
has hepatitis C
“Grammy-winning singer Natalie Cole has been diagnosed with hepatitis C,
her publicist said in a statement Wednesday. Hepatitis C is a liver disease
spread through contact with infected blood. The statement said the disease was
revealed during a routine examination and was likely caused by her drug use
years ago.
‘I've been so fortunate to have learned so much from my past experiences,’ said Cole. ‘I am embraced by the love and support of my family and friends; I am committed to my belief in myself and in my abiding faith to meet this challenge with a heartfelt optimism and determination. This is how I intend to deal with this current challenge in my life.’” Read more…
Improved culture system for hepatitis C
virus infection
“A University of California, San Diego School of Medicine researcher has
developed the first tissue culture of normal, human liver cells that can model
infection with the Hepatitis C virus (HCV) and provide a realistic environment
to evaluate possible treatments. The novel cell line will allow pharmaceutical
companies to effectively test new drug candidates or possible vaccines for the
HCV infection, which afflicts about 170 million people worldwide. Currently,
there is no animal model that is effective for testing such therapies.
‘This is the first efficient and consistent model system for HCV to be developed,’ said Buck, adding that it will now enable researchers not only to conduct mechanistic experiments in culture, such as blocking the virus pathways, but also to more effectively screen possible therapies for HCV. ‘There is a need for new treatments, and for development of a possible vaccine for HCV. Now we have a model system to support work by investigators in this area.’ Read more…
Hepatitis
bout ignited Nebraska woman's activism against medical contamination
“Evelyn McKnight beat the breast
cancer that could have killed her, but her doctor's unsanitary practice
infected her and 98 other patients with another life-threatening disease:
hepatitis C. As a result, McKnight, an audiologist in Fremont, Neb., last year
founded a nonprofit organization Hepatitis Outbreaks National Organization for
Reform (HONOReform) to lobby for state and federal laws protecting patients
from substandard care.” Read
more…
County hepatitis C
numbers lead to increased screening
High-risk people encouraged to visit county clinic
“SUMMIT COUNTY, CO — Local health officials are concerned that increasing
numbers of hepatitis-C cases are going undetected as exposure climbs. The
Summit County Community Care Clinic has confirmed two positive tests for the
disease since January and has records of 30 county residents who have been
exposed, said Carolynn Lyle, a certified physician’s assistant at the clinic.
The actual number of people infected is likely much higher, she said.
Deborah Miliner, also a PA-C with the clinic, said many can carry the disease for 20 or 30 years without symptoms. ‘That’s the bummer: They might not have any symptoms ever, except that (their) liver is slowly dying,’ she said.” Read more…
Many locals may be
hepatitis C positive
“Doctors say between 10,000 and 20,000 people with Hepatitis C live in the
collective New Braunfels, Kyle, Wimberley and Lockhart area — and many are
wholly unaware they’ve contracted the blood-borne disease. ‘With most of the
patients we’re treating now, (the diagnosis) was picked up incidentally,’ said
Dr. Juan Guerrero, hepatologist with San Antonio’s UT Health Science Center. A
liver transplant isn’t always needed, he said, but ‘by the time symptoms
present themselves it’s usually too late’ to go another route.” Read
more…
Genelabs, Taiwan
company collaborate on hepatitis C research
“Genelabs Technologies Inc. said Wednesday it will collaborate with two
entities to research and develop compounds that target the hepatitis C virus.
Redwood City-based Genelabs said the agreement includes the National Health
Research Institutes, a nonprofit foundation established by the government of
the Republic of China, and Genovate Biotechnology Co. Ltd., a biopharmaceutical
company in Taiwan. Financial details were not disclosed.
In June Genelabs said Gilead Sciences Inc. ended a deal between the two companies to study a possible hepatitis C treatment. Genelabs said at the time it would get back all rights to the compounds developed in the deal with Foster City's Gilead.” Read more…
2 dates identified in
Vegas hepatitis C outbreak
“The Southern Nevada Health District is identifying the two dates in 2007
when officials believe hepatitis C was transmitted between patients at the
Endoscopy Center of Southern Nevada. In a report prepared for the district
board on Thursday, officials say genetic testing traced the virus to patients
treated on July 25, 2007, and on Sept. 21, 2007.
On Wednesday, officials said a ninth case of hepatitis C was linked to the Las Vegas clinic and a sister facility, the Desert Shadow Endoscopy Center. In the biggest public health notification in U.S. history, the district last February advised some 50,000 clinic patients to get blood tests for hepatitis B, C and HIV, the virus that causes AIDS. Authorities say patients were exposed to the virus when clinic staff reused syringes and medicine vials.” Read more…
Researchers disprove
long-standing belief about HIV treatment
“Researchers at Wake Forest University Baptist Medical Center have
disproved a long-standing clinical belief that the hepatitis C virus slows or
stunts the immune system’s ability to restore itself after HIV patients are
treated with a combination of drugs known as the ‘cocktail.’
Hepatitis C (HCV) infection is more serious in HIV-infected people, leading to rapid liver damage, according to the Centers for Disease Control. Intravenous drug use is a main method of contraction for both HIV and HCV and 50 to 90 percent of HIV-infected drug users are also infected with HCV.
The Wake Forest Baptist study looked at whether having HCV coinfection impairs immune restoration in patients receiving highly active anti-retroviral therapy (HAART) to suppress their HIV infection. The results appear in the July issue of Aids Research and Human Retroviruses.
The research focused on levels of CD4 cells, the specific type of immune cell that is attacked by the HIV virus, and their ability to rebuild after HIV is suppressed. ‘We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4,’ said Marina Nunez, M.D., lead researcher and an assistant professor of infectious diseases. ‘Some studies suggested it was because of the hepatitis C. This study says it’s not the presence of active hepatitis C replication.’
Thus, said Nunez, genetic factors involved in the immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors might explain the blunted immune restoration observed in some coinfected patients. ‘Research efforts should pursue the role of those other factors in the immune restoration,’ she said.” Read more…
Idenix Pharmaceuticals advances HCV
discovery program to clinic
Initiates IDX184 phase I clinical study and advances HCV protease inhibitor and
non-nucleoside polymerase inhibitor clinical candidates into IND-enabling
preclinical studies.
“Indenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the
discovery and development of drugs for the treatment of human viral and other
infectious diseases, today announced that it has initiated a first-in-man study
of IDX184 under a United States investigational new drug (IND) application.
IDX184 is a once-daily, oral nucleotide prodrug polymerase inhibitor for the
treatment of chronic hepatitis C. Today, Idenix also announced that is has
selected a lead clinical candidate (IDX375) from its HCV non-nucleoside polymerase
inhibitor discovery program and has advanced IDX375 into IND-enabling
pharmacokinetic and toxicology studies. Idenix has also advanced two protease
inhibitor drug candidates (IDX136 and IDX316) into IND-enabling pharmacokinetic
and toxicology studies.” Read
more…
Clinical
Trials, Cohort Studies, Pilot Studies
Lichen planus and
other cutaneous manifestations in chronic hepatitis C: pre- and
post-interferon-based treatment prevalence vary in a cohort of patients from
low hepatitis C virus endemic area. Maticic M, et al. J Eur Acad Dermatol
Venereol. 2008 Jul;22(7):779-88.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18452521&dopt=Abstract
Pregnancy
complications associated with hepatitis C: data from a 2003-2005 Washington
state birth cohort. Pergam SA, et al. Am J Obstet Gynecol. 2008
Jul;199(1):38.e1-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18486089&dopt=Abstract
Associations between
hepatitis C viremia and low serum triglyceride and cholesterol levels: A
community-based study. Dai Cy, et al. J Hepatol. 2008 Jul;49(1):9-16.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18486265&dopt=Abstract
Antiviral effects and
safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in
hepatitis C patients. Lawitz E, at al. J Hepatol. 2008 Aug;49(2):163-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18486984&dopt=Abstract
Metabolic factors and
risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a
follow-up study in Taiwan. Chen CL, et al. Gastroenterology. 2008
Jul;135(1):111-21.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18505690&dopt=Abstract
Erythropoiesis-stimulating
agent use for anemia induced by interferon-ribavirin treatment in patients with
hepatitis C virus infection is not associated with increased rates of
cardiovascular disease, thrombosis, malignancy, or death. Costiniuk CT,
Camacho F, and Cooper CL. Clin Infect Dis. 2008 Jul 15;47(2):198-202.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18532889&dopt=Abstract
Efficacy of low-dose intermittent
interferon-alpha monotherapy in patients infected with hepatitis C virus
genotype 1b who were predicted or failed to respond to pegylated interferon
plus ribavirin combination therapy. Akuta N, et al. J Med Virol. 2008
Aug;80(8):1363-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18551610&dopt=Abstract
Pioglitazone in
chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
Overkbeck K, et al. J Hepatol. 2008 Aug;49(2):295-298.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18555553&dopt=Abstract
Antiviral therapy for
recurrent hepatitis C after liver transplantation: sustained virologic response
is related to genotype 2/3 and response at week 12. Raziorrouh B, et al.
Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18617783&dopt=Abstract
Suitable treatment
period in patients with virological response during combination therapy of
peginterferon and ribavirin for chronic hepatitis C. Arase Y, et al. Intern
Med. 2008;47(14):1301-7. [ Epub 2008 Jul 15]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18628577&dopt=Abstract
The Response to
Pegylated Interferon Alpha 2a in Haemodialysis Patients with Hepatitis C Virus
Infection. Akhan SC, Kalender B, and Ruzgar M. Infection. 2008 Jul 15. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18629437&dopt=Abstract
Liver transplant for hepatitis C virus:
effect of using older donor grafts on short- and medium-term survival. Doyle
MB, et al. Arch Surg. 2008 Jul;143(7):679-85.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18645111&dopt=Abstract
Basic
and Applied Science, Pre-Clinical Studies
Fibrosis progression
rates between chronic hepatitis B and C patients with elevated alanine
aminotransferase levels. Fujiwara A,et al. J Gastroenterol.
2008;43(6):484-91.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18600393&dopt=Abstract
A set of reference
sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open
reading frame. Kuntzen T, et al. J Med Virol. 2008 Aug;80(8):1370-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18551618&dopt=Abstract
Histologic abnormalities are common in
protocol liver allograft biopsies from patients with normal liver function
tests. Abraham SC, et al. Am J Surg Pathol. 2008 Jul;32(7):965-73.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18460980&dopt=Abstract
Kinetics of hepatitis
C viral RNA and HCV-antigen during dialysis sessions: evidence for differential
viral load reduction on dialysis. Kaiser T, et al. J Med Virol. 2008
Jul;80(7):1195-201.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18461613&dopt=Abstract
Hepatitis C virus
infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.
Yeh CT, et al. Biochem Biophys Res Commun. 2008 Jul 18;372(1):157-61.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18474223&dopt=Abstract
Efficient
trans-encapsidation of hepatitis C virus RNAs into infectious virus-like
particles.
Steinmann E, et al. J Virol. 2008 Jul;82(14):7034-46.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18480457&dopt=Abstract
Cryofibrinogen in
patients with hepatitis C virus infection. Delluc A, et al. Am J Med. 2008
Jul;121(7):624-31.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18589059&dopt=Abstract
Persistence of
hepatitis C virus in peripheral blood mononuclear cells of sustained viral
responders to pegylated interferon and ribavirin therapy. Gallegos-Orozco
JF, et al. Dig Dis Sci. 2008 Jul 2.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18594984&dopt=Abstract
Response to
interferon therapy affects risk factors for postoperative recurrence of
hepatitis C virus-related hepatocellular carcinoma. Uenishi T, et al. J
Surg Oncol. 2008 Jul 21.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18646001&dopt=Abstract
The impact of
combination therapy with peginterferon alfa-2a and ribavirin on the energy
intake and body weight of adult hepatitis C patients. Hamer C. J Hum Nutr
Diet. 2008 Jul 18.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18647213&dopt=Abstract
Hepatitis C
virus-specific T-cell immune responses in seronegative injection drug users.
Zeremski M, et al. J Viral Hepat. 2008 Jul 17.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18647233&dopt=Abstract
HIV/HCV
Coinfection
Human immunodeficiency virus-related
microbial translocation and progression of hepatitis C. Balagopal A, et al.
Gastroenterology. 2008 Jul;135(1):226-33.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18457674&dopt=Abstract
Management of chronic hepatitis C virus
infection in HIV-infected patients. Pol S and Soriano V. Clin Infect Dis.
2008 Jul 1;47(1):94-101.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18513148&dopt=Abstract
Role of pegylated interferon-alpha-2a and
ribavirin concentrations in sustained viral response in HCV/HIV-coinfected
patients. Lopez-Cortes L, et al. Clin Pharmacol Ther. 2008 Jul 2. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18596682&dopt=Abstract
Identification of novel markers for liver
fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based
approach. Suzman DL, et al. AIDS. 2008 Jul 31;22(12):1433-1439.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18614866&dopt=Abstract
Serum alpha-fetoprotein predicts virologic
response to Hepatitis C treatment in HIV coinfected patients. Carrat F, et
al. AIDS. 2008 Jul 31;22(12):1513-1515.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18614875&dopt=Abstract
Expansion of CD56- NK cells in chronic
HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated
IFNalpha and ribavirin. Gonzalez VD, et al. Clin Immunol. 2008
Jul;128(1):46-56. [Epub 2008 May 20]
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WCJ-4SJGWS5-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=2fe39e5675da69b6fe72e036b251ffe8
Liver fibrosis during an outbreak of acute
hepatitis C virus infection in HIV-infected men: a prospective cohort study.
Fierer DS, et al. J Infect Dis. 2008 Jul 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18627270&dopt=Abstract
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Martín-Carbonero L, et al. J Viral Hepat. 2008 Jul 10. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18637070&dopt=Abstract
Therapeutical aspects and outcome of
HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in
an Italian cohort. Righi E, et al. Infection. 2008 Jul 19. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18642111&dopt=Abstract
Complementary
& Alternative Therapy
Two flavonoids extracts from Glycyrrhizae
radix inhibit in vitro hepatitis C virus replication.
Sekine-Osajima Y, et al. Hepatol Res. 2008 Jul 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18647187&dopt=Abstract
Epidemiology, Diagnostics, and Miscellaneous
Works
Validation of a strategy for HCV antibody
testing with two enzyme immunoassays in a routine clinical laboratory. Vermeersch
P, Van Ranst M, and Lagrou K. J Clin Virol. 2008 Aug;42(4):394-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18448386&dopt=Abstract
Hepatitis C virus (HCV)-specific immune
responses of long-term injection drug users frequently exposed to HCV. Mizukoshi
E, et al. J Infect Dis. 2008 Jul 15;198(2):203-212.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18505381&dopt=Abstract
Factors influencing Hepatitis C virus
sero-prevalence among blood donors in north west Pakistan. Khattak MN, et
al. J Public Health Policy. 2008 Jul;29(2):207-25.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18523475&dopt=Abstract
Impact of viral eradication on mortality
related to hepatitis C: a modeling approach in France. Deuffic-Burban S, et
al. J Hepatol. 2008 Aug;49(2):175-83.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18538441&dopt=Abstract
The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. Ribes J, et al. J Hepatol. 2008 Aug;49(2):233-42.
Sustained virologic response to treatment
in 100% of patients recently infected, nosocomially, with HCV genotype 2. Sikuler
E, et al. J Clin Gastroenterol. 2008 Jul;42(6):730-733.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18574394&dopt=Abstract
External validation of the platelet
count/spleen diameter ratio for the diagnosis of esophageal varices in
hepatitis C virus-related cirrhosis. Agha A, et al. Dig Dis Sci. 2008 Jul 2.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18594972&dopt=Abstract
Epidemiological characteristics and medical
follow-up of 61 patients with acute hepatitis C identified through the
hepatitis C surveillance system in France. Brouard C, et al. Epidemiol
Infect. 2008 Jul;136(7):988-96.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=17697444&dopt=Abstract
Prevalence of infection with hepatitis B
and C viruses and co-infection with HIV in three jails: a case for viral
hepatitis prevention in jails in the United States. Hennessey KA, et al. J Urban Health. 2008 Jul
12; [Epub ahead of print]
http://www.springerlink.com/content/j43m23mq1518841j/
Evaluation of the new ARCHITECT anti-HCV
screening test under routine laboratory conditions. Berger A, et al. J Clin
Virol. 2008 Jul 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18635393&dopt=Abstract
Active intravenous drug use during chronic
hepatitis C therapy does not reduce sustained virological response rates in
adherent patients. Bruggmann P, et al. J Viral Hepat. 2008 Jul 10. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18637072&dopt=Abstract
Hepatocellular carcinoma in long-term
sustained virological responders following antiviral combination therapy for
chronic hepatitis C. Scherzer TM, et al. J Viral Hepat. 2008 Jul 10. [Epub
ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18637075&dopt=Abstract
A continuous (13)C methacetin breath test
for noninvasive assessment of intrahepatic inflammation and fibrosis in
patients with chronic HCV infection and normal ALT.
Lalazar G, et al. J Viral Hepat. 2008 Jul 10. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18638013&dopt=Abstract
Prevalence and genotype distribution of
hepatitis C virus among apparently healthy individuals in Mongolia: a
population-based nationwide study. Baatarkhuu O, et al. Liver Int. 2008 Jul
16. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18647237&dopt=Abstract
Clinicopathological features of elderly
patients with hepatitis C virus-related hepatocellular carcinoma. Miki D,
et al. J Gastroenterol. 2008;43(7):550-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18648742&dopt=Abstract